Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance study of [14C]-PF-07304814 in healthy volunteers
NCT05050682Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2021
- Primary completion
- Dec 2021
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lufotrelvir, sponsored by Pfizer. Primary endpoints: Amount of [14C] Recovered in Urine as Percent of Total [14C] Dose Administered at 216 hours, Amount of [14C] Recovered in Feces as Percent of Total [14C] Dose Administered at 216 hours and 19 more. Started Oct 2021; status: completed.
02
Drugs
lufotrelvir
Beyond the preview
Go deeper on NCT05050682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05050682.